Article (Scientific journals)
Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
Comté, Laetitia; Vrijens, Bernard; Tousset, Eric et al.
2007In Journal of Pharmacokinetics and Pharmacodynamics, 34 (4), p. 549-558
Peer Reviewed verified by ORBi
 

Files


Full Text
corrected_post-review_LComte_article.pdf
Author postprint (114.03 kB)
Request a copy

The original publication is available at www.springerlink.com


All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
adherence; compliance-HIV; time history of drug intake; PI concentration in plasma; drug dosing regimens; once-daily dosing; twice-daily dosing; pharmacokinetics; pharmacodynamics; systems therapeutics
Abstract :
[en] Once-daily dosing almost invariably shows a slightly higher percentage of prescribed doses taken than does twice-daily dosing. Many pharmaceutical scientists, regulators, and prescribers have considered this finding to signify the therapeutic superiority of once-daily dosing. The therapeutically more relevant question, however, is not the percentage of prescribed doses taken but the comparative impact of missed doses on the pharmacologic effects of a drug under the two dosing regimens. A key point in this regard is that the pharmacokinetic equivalent of a single missed once-daily dose is 2-3 sequentially omitted twice-daily doses. Thus, an important parameter in comparing the two regimens is the probability of two or three twice-daily doses being sequentially omitted, versus the probability of missing a single once-daily dose. Our data indicate that the probability of sequential omission of 2-3 twice daily doses is half the probability of omission of a single once-daily dose. For that reason, a twice-daily regimen could prove to be superior to a once-daily regimen in maintaining drug concentrations within a therapeutically desirable range. A more important consideration, however, is to maintain not just the concentration of drug in plasma, but the drug's therapeutic action. The duration of therapeutic drug action following a last-taken dose is not only drug-specific, but also, for some drug, dependent on the pharmacodynamic properties. Judging the comparative superiority of one dosing regimen over another requires knowledge of the drug's duration action after a last-taken dose, plus knowledge of the comparative probabilities of the various patterns of dose omission. When applied to HIV protease inhibitors, a twice-daily regimen appears to be better than an once-daily regimen in maintaining therapeutically effective drug actions.
Disciplines :
Pharmacy, pharmacology & toxicology
Physical, chemical, mathematical & earth Sciences: Multidisciplinary, general & others
Author, co-author :
Comté, Laetitia ;  Université de Liège - ULiège > Département de mathématique > Statistique (aspects expérimentaux)
Vrijens, Bernard  ;  Université de Liège - ULiège > Département de mathématique
Tousset, Eric;  Pharmionic Research Center
Gérard, Paul ;  Université de Liège - ULiège > Département de mathématique > Statistique (aspects expérimentaux)
Urquhart, John;  University of California, San Francisco Medical Center > Department of Biopharmaceutical Sciences > Center for Drug Development Science
Language :
English
Title :
Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
Publication date :
August 2007
Journal title :
Journal of Pharmacokinetics and Pharmacodynamics
ISSN :
1567-567X
eISSN :
1573-8744
Publisher :
Springer/Plenum Publishers, New York, United States - New York
Volume :
34
Issue :
4
Pages :
549-558
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 13 July 2009

Statistics


Number of views
124 (2 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
42
Scopus citations®
without self-citations
31
OpenCitations
 
36

Bibliography


Similar publications



Contact ORBi